<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport"
	content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca Oncology">
<link rel="stylesheet" href="css/style.css" />
<link rel="stylesheet" href="css/animate.min.css" />
<style type="text/css">
    h1 {line-height: 27px;}
    .explanation {top: 133px; position: relative; line-height:20px; width:100%;}
    .atlas { list-style:none;  position: relative; font-family:'HelveticaNeueLTStd-LtCn';top: 255px; left: 5px;font-size: 10px;}
    .content ol {position: relative; top: 166px; margin-left: 0px;  counter-reset: listStyle; font-size: 18px;  line-height: 25px; }
    .content ol > li {font-family: 'HelveticaNeueLTStd-Bd'; counter-increment: listStyle; display:inline-block; margin-bottom: 15px; letter-spacing: 0.35px; list-style: none;}
    .content ol > li:before {margin-right: 8px; content: counter(listStyle); display: inline-block; float:left; height: 35px; width:10px;}
    .content ol > li:nth-of-type(2) {margin-bottom: 6px;}
    .content ul > li {list-style: disc; color:#666767;font-family: 'HelveticaNeueLTStd-Lt'; margin-left:36px; margin-top: 5px;}
</style>
</head>
<body class='nolvadex'>
	<div class='container'>
        <div class="content">
	        <h1>Tamoxifen offers a long period of protection after treatment cessation and thus
substantially improves the benefit-to-harm ratio of the drug for breast cancer
prevention [in high risk women]<sup>2*</sup></h1>
	        <div class="explanation">*When compared to placebo</div>
	        
	        <ol>
	          <li>Nolvadex is now PBS listed for the primary reduction of breast cancer risk in women<br/>at a lifetime breast cancer risk of 1.5 to 3 times the population average<sup>1-3</sup></li>
	          <li>Dosage for the primary reduction of breast cancer risk: 20 mg daily for 5 years<sup>1</sup></li>
              <li>AstraZeneca continues to invest in treatments like Nolvadex to ensure women at high<br/>
risk of breast cancer have treatment options.
                    <ul><li>‘Tick the box for no brand substitution’ to support branded Nolvadex</li></ul>
              </li>

	          <li>Nolvadex safety and tolerability:<sup>2</sup>
	            <ul>
	               <li>No new late toxicities have been identified</li>
                   <li>Early excess of endometrial cancers have translated into an increased number of deaths<br/>
(tamoxifen vs placebo, not significant) and should be considered in risk/benefit analysis for<br/>each patient</li>
                </ul>
	          </li>
	        </ol>
	        
            <span class="atlas">ATLAS Approval Number: 434103.022. Date prepared: November 2016.</span>
		</div>
	    
		<span class='logo'></span>
		<div class="glasspane"></div>
		<div class="popup">
			<div class='ref'>
				<p>Reference:</p>
				<ol>
					<li>Nolvadex Approved Product<br />Information. April 2016.</li>
					<li>Cuzick J et al. <i>Lancet Oncol</i><br />
2015; 16: 67–75.</li>
                    <li>www.pbs.gov.au<br />
(accessed 1st October 2016)</li>
        		</ol>
			</div>
			
		</div>
		<div class='footer'></div> 
		<div class="controls">
            <span class="r"></span>
            <span class="i disabled"></span>
            <span class="p pi"></span>
        </div>
	</div>
	<script type="text/javascript">
       var idx = 'N05';
    </script>
    <script src="js/jquery-3.1.1.min.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/touchy.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/script.js" type="text/javascript" charset="utf-8"></script>
    <script src="js/variables.js" type="text/javascript" charset="utf-8"></script>
</body>
</html>
